Agnostic.com

4 9

Fantastic news!

Girl, 13, ‘leukaemia-free’ after world-first use of cell engineering therapy

Scientists hope the experimental therapy will pave the way for new treatments and ‘ultimately better futures for sick children’.

A 13-year-old girl who relapsed with a particular type of blood cancer is now leukaemia-free after a world-first use of what scientists have described as the most sophisticated cell engineering to date.

Alyssa, whose family did not wish to give their surname, said she felt that taking the experimental new treatment for the disease would help others, adding “of course I’m going to do it”.

Scientists said that without the treatment, which came after chemotherapy and an initial bone marrow transplant failed to clear her cancer, her only next step would have been palliative care.

Speaking about the revolutionary new therapy, Alyssa said: “Once I do it, people will know what they need to do, one way or another, so doing this will help people – of course I’m going to do it.”

The teenager, from Leicester, received base-edited T-cells in the first ever use of a base-edited cell therapy at Great Ormond Street Hospital for Children (GOSH).

These pre-manufactured cells, from a healthy volunteer donor, were edited using new technology to allow them to hunt down and kill cancerous T-cells without attacking each other.

T-cells are a type of white blood cell which move around the body to find and destroy defective cells.

Alyssa, who was diagnosed with T-cell acute lymphoblastic leukaemia (T-ALL) in 2021, was given all the conventional treatments including chemotherapy and a bone marrow transplant, but the disease returned.

'This is a great demonstration of how, with expert teams and infrastructure, we can link cutting-edge technologies in the lab with real results in the hospital for patients.' - Professor Waseem Qasim

She then became the first patient enrolled onto a new clinical trial, funded by the Medical Research Council, during which she was given universal CAR (Chimeric Antigen Receptor) T-cells that had been pre-manufactured from a healthy volunteer donor in May this year.

The researchers described base-editing as chemically converting letters of the DNA code which carry instructions for a specific protein.

The edited CAR T-cells can be given to a patient so that they quickly find and destroy T-cells in the body, including cancerous ones, after which the person can have a bone marrow transplant to restore their depleted immune system.

Twenty-eight days after being given the treatment, Alyssa was in remission, researchers said, and was able to have a second bone marrow transplant.

She is said to be “doing well at home” as she recovers and continues with follow-up monitoring at GOSH.

'It’s our most sophisticated cell engineering so far and paves the way for other new treatments and ultimately better futures for sick children.' - Professor Waseem Qasim

It is hoped the research, due to be presented for the first time at the American Society of Haematology annual meeting in New Orleans in the US this weekend, could lead to new treatments and “ultimately better futures for sick children”.

Scientists aim to recruit up to 10 patients who have T-cell leukaemia and have exhausted all conventional options for the clinical trial into the new treatment.

Medics at GOSH hope that if it is successful it can be offered to children earlier in their treatment when they are less sick and that it can be used for other types of leukaemia in future.

Potential patients for trials will be referred by NHS specialists.

Professor Waseem Qasim, consultant immunologist at GOSH, said: “This is a great demonstration of how, with expert teams and infrastructure, we can link cutting-edge technologies in the lab with real results in the hospital for patients. It’s our most sophisticated cell engineering so far and paves the way for other new treatments and ultimately better futures for sick children.

'Hopefully this can prove the research works and they can offer it to more children - all of this needs to have been for something.' - Alyssa’s mother Kiona

“We have a unique and special environment here at GOSH that allows us to rapidly scale up new technologies and we’re looking forward to continuing our research and bringing it to the patients who need it most.”

Alyssa’s mother Kiona said the family were “on a strange cloud nine” and that it was “amazing to be home”.

She added: “Hopefully this can prove the research works and they can offer it to more children – all of this needs to have been for something.”

[independent.co.uk]

Ryo1 8 Dec 11
Share

Enjoy being online again!

Welcome to the community of good people who base their values on evidence and appreciate civil discourse - the social network you will enjoy.

Create your free account

4 comments

Feel free to reply to any comment by clicking the "Reply" button.

2

My son had Myeloid Dysplasia from the age of 18 months. He is now 37. he was cured by a South American (Bolivia? Brazil?) naturopath. He gave my son a concoction that was the vilest tasting thing I have ever experienced, but it did the job.
He was lucky, many of his fellow patients did not make it despite transfusions and Chemo.
It is wonderful that the technology is now able to treat the range of blood cancers. It is the dawn of a new era of treatments. The road ahead will undoubtly be rocky, but at least we now have a road .

1

Very promising news, but before we get too excited let's wait for some time to pass so more data may be collected and analysed before releasing on the market. Still needs a bone marrow treatment so not a silver bullet cure.

puff Level 8 Dec 11, 2022

There is a lot of hope for what is to come.

@Ryo1 Which is good

2

Just as there have been Agricultural and industrial revolutions, and an age of chemistry, then an age of physics, we are now having a technological revolution, and an age of biology.

2

Awesome! More of this type of thing will be coming . . . .

Write Comment
You can include a link to this post in your posts and comments by including the text q:699789
Agnostic does not evaluate or guarantee the accuracy of any content. Read full disclaimer.